Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07247097 · ClinicalTrials.gov registry record · Phase 2
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT07247097: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT07247097 is a Phase 2 study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 160 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07247097, a Phase 2 study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for patients with newly diagnosed, transplant ineligible/deferred multiple myeloma.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Daratumumab and Hyaluronidase-fihj
- DRUG Elranatamab (PF-06863135)
- DRUG Bortezomib for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2035-12-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07247097
The ClinicalTrials.gov registry entry for NCT07247097 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT07247097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07247097 about?
NCT07247097 is a clinical study titled "ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma". This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for patients with newly diagnosed, transplant ineligible/deferred multiple my...
What is the current status of trial NCT07247097?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2026-08-01. Estimated completion is 2035-12-01.
What interventions are being tested in trial NCT07247097?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab and Hyaluronidase-fihj (DRUG), Elranatamab (PF-06863135) (DRUG), Bortezomib for Injection (DRUG).
Who is sponsoring clinical trial NCT07247097?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.